Monoclonal antibodies in cervical malignancy-related HPV

Abstract

Despite many efforts to treat HPV infection, cervical cancer survival is still poor for several reasons, including resistance to chemotherapy and relapse. Numerous treatments such as surgery, radiation therapy, immune cell-based therapies, siRNA combined with various drugs, and immunotherapy are being studied and performed to provide the best treatment. Depending on the stage and size of the tumor, methods such as radical hysterectomy, pelvic lymphadenectomy, or chemotherapy can be utilized to treat cervical cancer. While accepted, these treatments lead to interruptions in cellular pathways and immune system homeostasis. In addition to a low survival rate, cervical neoplasm incidence has been rising significantly. However, new strategies have been proposed to increase patient survival while reducing the toxicity of chemotherapy, including targeted therapy and monoclonal antibodies. In this article, we discuss the types and potential therapeutic roles of monoclonal antibodies in cervical cancer.

Intervenções Inovadoras Na Promoção Da Saúde: Vacinas Terapêuticas E Estratégias De Prevenção Do HPV

“…A imunoterapia estimula o sistema imunológico do paciente a reconhecer e combater as células tumorais de forma mais eficaz (KOURY et al, 2018). Essas terapias mais recentes buscam minimizar efeitos adversos e oferecer uma abordagem mais específica contra o câncer cervical, seja de forma individual ou como terapia combinada (AGHBASH et al, 2022). Nesse sentido, as vacinas terapêuticas representam uma estratégia promissora em imunoterapia (LIU et al, 2022).…”

Current Methods and Advances in the Immunotherapy Treatment of Non-Ovarian Gynaecological Cancers

“…However, the sample size was small (n = 24; cervical = 19; vaginal/vulvar = 5) and more justifications are needed. Cemiplimab, another anti-PD-1 monoclonal antibody approved to treat squa-mous cell carcinoma in lung and skin cancers [150], was also shown to have preliminary clinical activity in recurrent CC. Cemiplimab and chemotherapy were compared in the international multicentre, randomised, phase III trial GOG-3016 (NCT03257267), which included 608 patients (304 in each arm) and ran between 2017 and 2020.…”

The effect of Wnt/β-catenin signaling on PD-1/PDL-1 axis in HPV-related cervical cancer

“…Nivolumab, pembrolizumab, and atezolizumab are monoclonal antibodies that target the PD-1/PD-L1 and CTLA-4 pathways as immunotherapy (fda. gov) [169,171]. It's worth noting that PD-1/PD-L1 immunotherapy antibodies are related to higher numbers of tumor-infiltrating T CD8+ cells, reinvigorate anti-tumor immunity, and improve patient outcomes [172,173].…”

“…Wnt/β-catenin signaling pathway leads to ICI resistance therapy In recent years, treating various solid tumors, such as lung cancer, kidney cancer, and cervical malignancy, through the inhibition of immune checkpoints PD-1/PD-L1 has achieved significant results [171,193]. However, it has been reported that the response to anti-PD-1/PD-L1 monotherapy depends on the extent of tumor-infiltrating lymphocytes [194].…”

“…In addition to the mentioned investigators, it has been shown that natural compounds can also be used as a combination therapy in addition to effective prevention and treatment by affecting the Wnt/β-catenin signaling pathway, leading to an increase in the effect of ICI [213]. In this regard, in phase II clinical trial in patients with cervical cancer and resistant to treatment, it was observed that following the combination therapy of pembrolizumab as an anti-PD-L1 drug along with vitamin D (as a concomitant drug) and curcumin (drug complement), the anti-tumor immune response is strengthened (trial number: NCT03192059) [171,213].…”